Triple Negative Breast Cancer, Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Cancer, Stage IV Breast Cancer and Triple-negative Breast Cancer Clinical Trial Using cisplatin, laboratory biomarker analysis, GDC -0941, pharmacological study and dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI

- The folks at Vanderbilt-Ingram Cancer Center are studying the effects of cisplatin; laboratory biomarker analysis; pharmacological study; dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI; GDC -0941 on Triple Negative Breast Cancer, Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Cancer, Stage IV Breast Cancer and Triple-negative Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start September 2013 and is expected to end circa January 2016.

800-811-8480
Overall Study Contact Info
StatusName Contact Phone
RecruitingVICC Clinical Trials Information Program800-811-8480

This study is officially titled, "A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer."

Locations

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.